| Market cap | $459.47B |
|---|---|
| Enterprise value | $371.40B |
| Revenue | $81.796B |
|---|---|
| EBITDA | $28.853B |
| Income | $38.476B |
| Revenue Q/Q | -13.59% |
| Revenue Y/Y | -15.03% |
| P/E | 9.54 |
|---|---|
| Forward P/E | 13.89 |
| EV/Sales | 4.54 |
| EV/EBITDA | 12.87 |
| EV/EBIT | 8.83 |
| PEG | 3.79 |
| Price/Sales | 5.62 |
| P/FCF | 24.57 |
| Price/Book | 6.68 |
| Book/Share | 21.80 |
| Cash/Share | 7.27 |
| FCF yield | 4.07% |
| Volume | 6.035M / 7.022M |
|---|---|
| Relative vol. | 0.86 × |
| EPS | 15.26 |
|---|---|
| EPS Q/Q | -1.92% |
| Est. EPS Q/Q | 4.69% |
| Profit margin | 41.28% |
|---|---|
| Oper. margin | 25.24% |
| Gross margin | 68.82% |
| EBIT margin | 51.41% |
| EBITDA margin | 35.27% |
| Ret. on assets | 22.07% |
|---|---|
| Ret. on equity | 53.97% |
| ROIC | 21.22% |
| ROCE | 34.12% |
| Debt/Equity | 1.44 |
|---|---|
| Net debt/EBITDA | 1.29 |
| Current ratio | 1.17 |
| Quick ratio | 0.94 |
| Volatility | 1.42% |
|---|---|
| Beta | 0.22 |
| RSI | 41.96 |
|---|
| Insider ownership | 0.09% |
|---|---|
| Inst. ownership | 70.32% |
| Shares outst. | 2.407B |
|---|---|
| Shares float | 0.000 0.00% |
| Short % of float | 0.49% |
| Short ratio | 1.94 |
| Dividend | $4.81 |
|---|---|
| Dividend yield | 3.30% |
| Payout ratio | 31.52% |
| Payment date | N/A |
| Ex-dividend date | N/A |
| Earnings date | 17 Jul 2024 |
Tuesday, 18 June 2024
|
|
| J&J hit with new class action over talc seeking medical monitoring for cancer | |
Thursday, 6 June 2024
|
|
| Is Johnson & Johnson the Best Mega-Cap Dividend Aristocrat Stock? | |
Friday, 31 May 2024
|
|
| The Best Place in Oklahoma for a Couple to Live on Only Social Security | |
| The Most Profitable Biotechnology Company in the World | |
Wednesday, 29 May 2024
|
|
| Sarepta Therapeutics Set to Join S&P MidCap 400 | |
| Johnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial | |
Tuesday, 28 May 2024
|
|
| Johnson & Johnson to Obtain Rights to a Clinical-Stage Bispecific Antibody to Address Distinct Patient Needs in Atopic Dermatitis | |
Wednesday, 22 May 2024
|
|
| Is Eli Lilly and Company the Largest Publicly Traded Healthcare Company? | |
| Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies | |
Monday, 20 May 2024
|
|
| Johnson & Johnson's Dividend Analysis | |
Tuesday, 14 May 2024
|
|
| Is Ardagh Metal Packaging SA the Best High-Dividend Penny Stock to Buy Now? | |
Monday, 13 May 2024
|
|
| Asian Stocks Set for Cautious Open as CPI Looms: Markets Wrap | |
| Johnson & Johnson to sell remaining stake in Kenvue | |
Wednesday, 8 May 2024
|
|
| 10 Future Dividend Kings in the Next 5 Years or Less | |
Tuesday, 7 May 2024
|
|
| 15 Best S&P 500 Dividend Stocks To Buy Now | |
Monday, 6 May 2024
|
|
| Johnson & Johnson Advances Its Two Bladder Cancer Studies, Releases Latest Data | |
| 10 Best May Dividend Stocks To Buy | |
Friday, 3 May 2024
|
|
| 30 Most Profitable Companies with Highest Margins in the World | |
| Intuitive Surgical Builds On Its Robotic Surgery Prowess. But Challengers Are Coming. | |
Wednesday, 1 May 2024
|
|
| J&J subsidiary proposes paying about $6.48B over 25 years to settle talc lawsuits | |
| J&J advances $6.475 billion settlement of talc cancer lawsuits | |
Monday, 29 April 2024
|
|
| J&J, Bristol Myers lose challenges to US drug price negotiation program | |
| Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks | |
Sunday, 28 April 2024
|
|
| Dividend Stock Portfolio For Income: Top 15 Stocks | |
Saturday, 27 April 2024
|
|
| 10 Best Long Term Low Risk Stocks to Buy | |
Wednesday, 24 April 2024
|
|
| 14 Dividend Growth Stocks with Highest Growth Rates | |
Monday, 22 April 2024
|
|
| 10 Best Performing Biotech ETFs in 2024 | |
Sunday, 21 April 2024
|
|
| 10 Stocks American Politicians are Buying in 2024 | |
| 10 Best Soaps and Cleaning Materials Stocks to Buy | |
| Insider |
Trans.
Transaction
|
Total value |
|---|---|---|
| John C Reed EVP, Innovative Medicine, R, and D | Option 1 May 2024 | $3,364,511 |
| Vanessa Broadhurst EVP and Global Corp Affairs | Sale 13 Mar 2024 | $1,441,765 |
| Kathryn E Wengel EVP, Chief TO, and Risk Officer | Option 13 Feb 2024 | $101,862 |
| Joseph J Wolk Exec VP and CFO | Option 13 Feb 2024 | $278,517 |
| Jennifer L Taubert EVP and WWC. Innovative Medicine | Option 13 Feb 2024 | $203,724 |
| James D. Swanson EVP and CIO | Option 13 Feb 2024 | $69,942 |
| Timothy Schmid EVP, WW Chair, and MedTech | Option 13 Feb 2024 | $78,079 |
| William Hait EVP, Chief EI, and Med Officer | Option 13 Feb 2024 | $130,496 |
| Elizabeth Forminard Executive VP and General Counsel | Option 13 Feb 2024 | $101,862 |
| Peter Fasolo Exec VP and Chief HR Officer | Option 13 Feb 2024 | $144,735 |
| Joaquin Duato CEO and Chairman of the Board | Option 13 Feb 2024 | $542,951 |
Powered by
Robintrack.
Price target
Current $145.65
Average $166.55
Low $139
High $180
Dividends
| Ex-dividend date | N/A | Frequency | Quarterly | Annual dividend | +5.62% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 3.30% | Growth period | 53 years |
| Last dividend date | Yield 3 years | 2.94% | Growth 3 years | +5.70% | |
| Last dividend | Yield 5 years | 2.76% | Growth 5 years | +5.83% |
| Insider | Age | Since | Compensation |
|---|---|---|---|
| Alex Gorsky (59) Chairman of the Board and Chief Executive Officer since 2012 | 59 | 2012 | $25,365,800 |
| Paulus Stoffels (58) Vice Chairman- Executive Committee and Chief Scientific Officer since 2018 | 58 | 2018 | $14,067,800 |
| Joaquin Duato (57) Vice Chairman - Executive Committee since 2018 | 57 | 2018 | $13,419,300 |
| Joseph Wolk (53) Chief Financial Officer and Executive Vice President since 2018 | 53 | 2018 | $7,497,690 |
| Jennifer Taubert (56) Executive Vice President - Worldwide Chairman and Pharmaceuticals since 2018 | 56 | 2018 | $7,097,300 |
| Michael Ullmann (61) Executive Vice President and General Counsel since 2016 | 61 | 2016 | $5,336,150 |
| Alex Gorsky (61) Exec. Chairman | 61 | $4,999,325 | |
| Peter Fasolo (57) Chief Human Resource Officer and Executive Vice President since 2016 | 57 | 2016 | $3,621,280 |
| Dr. Paulus A. Stoffels M.D., Ph.D. (58) Chief Scientific Officer | 58 | $3,361,844 | |
| Joaquin Duato (58) CEO and Director | 58 | $2,887,910 | |
| Joseph J. Wolk CPA (54) Exec. VP and CFO | 54 | $2,577,183 | |
| Joseph J. Wolk C.P.A. (54) Exec. VP and CFO | 54 | $1,976,200 | |
| Jennifer L. Taubert (57) Exec. VP and Worldwide Chairman of Pharmaceuticals | 57 | $1,921,544 | |
| Anne Mulcahy (67) Lead Independent Director since 2012 | 67 | 2012 | $359,979 |
| Charles Prince (70) Independent Director since 2006 | 70 | 2006 | $344,979 |
| Mary Beckerle (65) Independent Director since 2015 | 65 | 2015 | $344,979 |
| Ronald Williams (70) Independent Director since 2011 | 70 | 2011 | $334,979 |
| D. Scott Davis (68) Independent Director since 2014 | 68 | 2014 | $329,979 |
| A. Eugene Washington (69) Independent Director since 2012 | 69 | 2012 | $324,979 |
| Jennifer Doudna (56) Independent Director since 2018 | 56 | 2018 | $324,979 |
| Mark McClellan (56) Independent Director since 2013 | 56 | 2013 | $304,979 |
| Ian Davis (69) Independent Director since 2010 | 69 | 2010 | $304,979 |
| Marillyn Hewson (66) Independent Director since 2019 | 66 | 2019 | $80,520 |
| Mark Weinberger (58) Independent Director since 2019 | 58 | 2019 | $8,877 |
| Hubert Joly (60) Independent Director since 2019 | 60 | 2019 | $8,877 |
| Christopher DelOrefice | 2019 | ||
| Kathryn Wengel (54) Executive Vice President and Chief Global Supply Chain Officer since 2018 | 54 | 2018 | |
| Michael Sneed (60) Executive Vice President - Global Corporate Affairs and Chief Communication Officer since 2018 | 60 | 2018 | |
| Thibaut Mongon (50) Executive Vice President, Worldwide Chairman, and Consumer since 2018 | 50 | 2018 | |
| Ashley McEvoy (49) Executive Vice President - Worldwide Chairman and Medical Devices since 2018 | 49 | 2018 | |
| Dr. Guy J. Lebeau M.D. | |||
| Dr. Peter M. Fasolo Ph.D. (58) Exec. VP and Chief HR Officer | 58 | ||
| Michael H. Ullmann (62) Exec. VP and Gen. Counsel | 62 | ||
| Jessica Moore | |||
| Ashley Watson (51) Chief Compliance Officer | 51 | ||
| James Swanson | |||
| Robert J. Decker Jr. (49) Controller and Chief Accounting Officer | 49 |
Johnson & Johnson is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods.
- Health Care > Pharmaceuticals
- Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick 08933, United States
- 732 524 0400
- Investor relations
Dividends
| Ex-dividend date | N/A | Frequency | Quarterly | Annual dividend | +5.62% |
|---|---|---|---|---|---|
| Next dividend | N/A | Dividend yield | 3.30% | Growth period | 53 years |
| Last dividend date | Yield 3 years | 2.94% | Growth 3 years | +5.70% | |
| Last dividend | Yield 5 years | 2.76% | Growth 5 years | +5.83% |
Quarterly EPS estimates
Profit margin
Debt to assets
Cash flow
Balance sheet
XSLX
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Current assets | |||||
| Cash | $25,473 | $21,859 | |||
| Short term investments | $745 | $1,068 | |||
| Net receivables | $14,946 | $14,873 | |||
| Inventory | $11,383 | $11,181 | |||
| Total current assets | $57,002 | $53,495 | |||
| Long term investments | |||||
| Property, plant & equipment | $19,632 | $19,898 | |||
| Goodwill & intangible assets | $70,902 | $70,733 | |||
| Total noncurrent assets | $114,964 | $114,063 | |||
| Total investments | $745 | $1,068 | |||
| Total assets | $171,966 | $167,558 | |||
| Current liabilities | |||||
| Accounts payable | $8,174 | $9,632 | |||
| Deferred revenue | |||||
| Short long term debt | $8,550 | $3,451 | |||
| Total current liabilities | $48,725 | $46,282 | |||
| Long term debt | $25,082 | $25,881 | |||
| Total noncurrent liabilities | $53,221 | $52,502 | |||
| Total debt | $33,632 | $29,332 | |||
| Total liabilities | $101,946 | $98,784 | |||
| Stockholders' equity | |||||
| Retained earnings | $153,378 | $153,843 | |||
| Other stockholder equity | -$10,768 | -$12,527 | |||
| Total stockholder equity | $70,020 | $68,774 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Current assets | ||||
| Cash | $21,859 | $14,127 | ||
| Short term investments | $1,068 | $9,392 | ||
| Net receivables | $14,873 | $16,160 | ||
| Inventory | $11,181 | $12,483 | ||
| Total current assets | $53,495 | $55,294 | ||
| Long term investments | ||||
| Property, plant & equipment | $19,898 | $19,803 | ||
| Goodwill & intangible assets | $70,733 | $93,556 | ||
| Total noncurrent assets | $114,063 | $132,084 | ||
| Total investments | $1,068 | $9,392 | ||
| Total assets | $167,558 | $187,378 | ||
| Current liabilities | ||||
| Accounts payable | $9,632 | $11,703 | ||
| Deferred revenue | ||||
| Short long term debt | $3,451 | $12,771 | ||
| Total current liabilities | $46,282 | $55,802 | ||
| Long term debt | $25,881 | $26,888 | ||
| Total noncurrent liabilities | $52,502 | $54,772 | ||
| Total debt | $29,332 | $39,659 | ||
| Total liabilities | $98,784 | $110,574 | ||
| Stockholders' equity | ||||
| Retained earnings | $153,843 | $128,345 | ||
| Other stockholder equity | -$12,527 | -$12,967 | ||
| Total stockholder equity | $68,774 | $76,804 | ||
Income statement
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Revenue | |||||
| Total revenue | $21,383 | $13,532 | |||
| Cost of revenue | $6,511 | $3,340 | |||
| Gross profit | $14,872 | $10,192 | |||
| Operating activities | |||||
| Research & development | $3,542 | $4,246 | |||
| Selling, general & administrative | $5,257 | $3,309 | |||
| Total operating expenses | $8,963 | $7,669 | |||
| Operating income | $5,909 | $2,523 | |||
| Income from continuing operations | |||||
| EBIT | $3,869 | $3,947 | |||
| Income tax expense | $459 | -$121 | |||
| Interest expense | $155 | $19 | |||
| Net income | |||||
| Net income | $3,255 | $4,049 | |||
| Income (for common shares) | $3,255 | $4,049 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $85,159 | $94,943 | ||
| Cost of revenue | $26,553 | $31,089 | ||
| Gross profit | $58,606 | $63,854 | ||
| Operating activities | ||||
| Research & development | $15,085 | $14,603 | ||
| Selling, general & administrative | $21,512 | $24,765 | ||
| Total operating expenses | $37,399 | $40,472 | ||
| Operating income | $21,207 | $23,382 | ||
| Income from continuing operations | ||||
| EBIT | $37,661 | $22,001 | ||
| Income tax expense | $1,736 | $3,784 | ||
| Interest expense | $772 | $276 | ||
| Net income | ||||
| Net income | $35,153 | $17,941 | ||
| Income (for common shares) | $35,153 | $17,941 | ||
Cash flows
| (in millions USD) | 31 Mar 2024 | 31 Dec 2023 | |||
|---|---|---|---|---|---|
| Net income | $3,255 | $4,049 | |||
| Operating activities | |||||
| Depreciation | $1,815 | $1,843 | |||
| Business acquisitions & disposals | -$1,601 | -$349 | |||
| Stock-based compensation | $302 | $178 | |||
| Total cash flows from operations | $3,657 | $7,863 | |||
| Investing activities | |||||
| Capital expenditures | -$807 | -$1,589 | |||
| Investments | $1,949 | $632 | |||
| Total cash flows from investing | -$464 | -$1,202 | |||
| Financing activities | |||||
| Dividends paid | -$2,869 | -$2,865 | |||
| Sale and purchase of stock | -$1,280 | -$29 | |||
| Net borrowings | $4,602 | -$1,377 | |||
| Total cash flows from financing | $546 | -$4,655 | |||
| Effect of exchange rate | -$125 | $125 | |||
| Change in cash and equivalents | $3,614 | $2,131 | |||
| (in millions USD) | 2023 | 2022 | ||
|---|---|---|---|---|
| Net income | $35,153 | $17,941 | ||
| Operating activities | ||||
| Depreciation | $7,486 | $6,970 | ||
| Business acquisitions & disposals | -$112 | -$17,109 | ||
| Stock-based compensation | $1,162 | $1,138 | ||
| Total cash flows from operations | $22,791 | $21,194 | ||
| Investing activities | ||||
| Capital expenditures | -$4,543 | -$4,009 | ||
| Investments | $5,521 | $8,976 | ||
| Total cash flows from investing | $878 | -$12,371 | ||
| Financing activities | ||||
| Dividends paid | -$11,770 | -$11,682 | ||
| Sale and purchase of stock | -$3,960 | -$4,706 | ||
| Net borrowings | -$2,953 | $7,424 | ||
| Total cash flows from financing | -$15,825 | -$8,871 | ||
| Effect of exchange rate | -$112 | -$312 | ||
| Change in cash and equivalents | $7,732 | -$360 | ||
Recent institutional transactions
| Quarter | Shareholder | Change |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|---|
| 2024 Q1 | Whalerock Point Partners |
-99.90%
|
33,684 | $5,328,494 |
| 2024 Q1 | Fmr |
-19.25%
|
16,877,555 | $2,669,860,608 |
| 2024 Q1 | Amundi |
+67.02%
|
9,989,313 | $1,457,107,837 |
| 2024 Q1 | Blackrock |
+1.83%
|
189,726,768 | $30,012,877,468 |
| 2024 Q1 | Price T Rowe Associates Inc md/ |
+16.79%
|
21,834,359 | $3,453,978 |
| 2024 Q1 | Deutsche Bank Ag\ |
+16.98%
|
14,099,265 | $2,230,362,731 |
| 2024 Q1 | Hsbc Holdings PLC |
+21.17%
|
9,986,772 | $1,579,753,101 |
| 2024 Q1 | Bank Of America Corp de/ |
+7.33%
|
23,723,391 | $3,752,803,156 |
| 2024 Q1 | Franklin Resources Inc |
+13.62%
|
12,459,481 | $1,970,965,324 |
| 2024 Q1 | Two Sigma Advisers, L.P. |
-64.01%
|
748,509 | $118,406,639 |
Institutional shareholders
| Shareholder | Stake |
Shares owned
Shares
|
Value (in thousands USD) |
|---|---|---|---|
| Vanguard Group Inc | 9.53% | 229,286,735 | |
| Blackrock | 7.88% | 189,726,768 | |
| State Street Corp | 5.55% | 133,519,781 | |
| Morgan Stanley | 1.77% | 42,549,943 | |
| Capital International Investors | 1.20% | 28,986,219 | |
| Norges Bank | 1.08% | 25,977,042 | |
| Wellington Management Group LL.P. | 0.99% | 23,746,968 | |
| Bank Of America Corp de/ | 0.99% | 23,723,391 | |
| Legal & General PLC | 0.97% | 23,261,197 | |
| Price T Rowe Associates Inc md/ | 0.91% | 21,834,359 |
Sign up